ADN-1184 a monoaminergic ligand with 5-HT6/7 receptor antagonist activity: Pharmacological profile and potential therapeutic utility

British Journal of Pharmacology

Volumn 171, Issue 4, 2014, Pages 973-984

  Kolaczkowski M ^a,b   Mierzejewski, P ^c   Bienkowski P ^c   Wesolowska A ^b   Newman Tancredi, A ^d  

^a Adamed Ltd ^*  (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^d NeuroAct Communication   (France)

Author keywords

ADN 1184; antipsychotics; behavioural pharmacology; BPSD; cognition; dementia; depression

Indexed keywords

ADN 1184; AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; DIZOCILPINE; HALOPERIDOL; IMIPRAMINE; LURASIDONE; PRAZOSIN; QUETIAPINE; RISPERIDONE; SEROTONIN 6 ANTAGONIST; SEROTONIN 7 ANTAGONIST; SEROTONIN ANTAGONIST; SULFONAMIDE; UNCLASSIFIED DRUG;

AGGRESSIVENESS; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR DISORDER; CATALEPSY; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG DOSE INCREASE; DRUG POTENCY; FORCED SWIM TEST; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LOCOMOTION; LOW DRUG DOSE; MALE; MEMORY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR BINDING;

ADN-1184; ANTIPSYCHOTICS; BEHAVIOURAL PHARMACOLOGY; BPSD; COGNITION; DEMENTIA; DEPRESSION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BRAIN; CHO CELLS; CRICETULUS; DIZOCILPINE MALEATE; HEK293 CELLS; HUMANS; ISOXAZOLES; LIGANDS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; SULFONAMIDES;

EID: 84893105972     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12509     Document Type: Article

References (60)

1. 7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 205: 119-128.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and, CGTP Collaborators, (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
3. Andiné P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Mårtensson E, et al. (1999). Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 290: 1393-1408.
4. Arnt J, (1982). Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 51: 321-329.
5. 6 receptor ligands and their antipsychotic potential. Int Rev Neurobiol 96: 141-161.
6. Arnt J, Bang-Andersen B, Dias R, Bøgesø KP, (2008). Strategies for pharmacotherapy of schizophrenia. Drugs Future 33: 777-791.
7. Bai YM, Chen T-T, Liou Y-J, Hong C-J, Tsai S-J, (2011). Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res 125: 179-186.
8. 1A activity: comparison with typical and atypical conventional antipsychotics. Behav Pharmacol 18: 103-118.
9. 7 receptor reverses working memory deficits in rats by normalizing cortical glutamate neurotransmission. PLoS ONE 6: e20210.
10. Bradford AM, Savage KM, Jones DNC, Kalinichev M, (2010). Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. Psychopharmacology (Berl) 212: 155-170.
11. 6 receptor agonists in rats. Psychopharmacology (Berl) 213: 499-507.
12. Carson S, McDonagh MS, Peterson K, (2006). A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. J Am Geriatr Soc 54: 354-361.
13. 6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Psychopharmacology (Berl) 222: 99-115.
14. De Deyn P, Jeste DV, Swanink R, Kostic D, Breder C, Carson WH, et al. (2005). Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 25: 463-467.
15. 7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol 19: 153-159.
16. 6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev Neurother 9: 1073-1085.
17. H. Lundbeck A/S (2012). Lundbeck's Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer's disease. Corp. Release 472: 1-4. Available at: http://investor. lundbeck.com/releasedetail.cfm?ReleaseID=677436 (accessed 23/10/2012).
18. 7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 206: 345-354.
19. Hersch EC, Falzgraf S, (2007). Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging 2: 611-621.
20. 6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease. Life Sci 84: 558-562.
21. 2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 7: 1507-1509.
22. 1A receptor activity. J Pharmacol Exp Ther 334: 171-181.
23. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y, (2007). Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-Avoidance test. Eur J Pharmacol 572: 160-170.
24. Jeste DV, Finkel SI, (2000). Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 8: 29-34.
25. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. (2008). ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33: 957-970.
26. Jones CA, Watson DJG, Fone KCF, (2011). Animal models of schizophrenia. Br J Pharmacol 164: 1162-1194.
27. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
28. Kołaczkowski M, Kowalski P, Jaśkowska J, Marcinkowska M, Mitka K, Bucki A, et al. (2012). Aryl sulfonamides for the treatment of CNS diseases. PCT Int Appl WO 2012035123.
29. Kołaczkowski M, Mierzejewski P, Bienkowski P, Wesolowska A, Newman-Tancredi A,. (2013). Targeting behavioural and psychological symptoms of dementia: comparison of antipsychotics and the novel compound ADN-1184 in rat models. European Neuropsychopharmacology 23: Supplement 2, Poster P.5.a.003
30. Lazareno S, Birdsall NJ, (1993). Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Pharmacol 109: 1110-1119.
31. Liperoti R, Pedone C, Corsonello A, (2008). Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol 6: 117-124.
32. 6 receptor antagonists in the social recognition procedure in rats: implication of the frontal cortex. Psychopharmacology (Berl) 196: 93-104.
33. 6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci 7: 36.
34. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
35. Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, et al. (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-Analysis. JAMA 306: 1359-1369.
36. Marcos B, García-Alloza M, Gil-Bea FJ, Chuang TT, Francis PT, Chen CP, et al. (2008). Involvement of an altered 5-HT -{6} receptor function in behavioral symptoms of Alzheimer's disease. J Alzheimers Dis 14: 43-50.
37. Marsh A, (1979). Visual hallucinations during hallucinogenic experience and schizophrenia. Schizophr Bull 5: 627-630.
38. 2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 11: 4419-4432.
39. Miller DD, (2000). Review and management of clozapine side effects. J Clin Psychiatry 61 (Suppl. 8): 14-17; discussion 18-19.
40. Morley-Fletcher S, Darnaudéry M, Mocaer E, Froger N, Lanfumey L, Laviola G, et al. (2004). Chronic treatment with imipramine reverses immobility behaviour, hippocampal corticosteroid receptors and cortical 5-HT(1A) receptor mRNA in prenatally stressed rats. Neuropharmacology 47: 841-847.
41. 1A receptor properties. Psychopharmacology (Berl) 216: 451-473.
42. Nobili A, Pasina L, Trevisan S, Riva E, Lucca U, Tettamanti M, et al. (2009). Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. Int Clin Psychopharmacol 24: 97-104.
43. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology (Berl) 90: 287-294.
44. Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, et al. (2012). N-methyl d-Aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res 9: 746-758.
45. Porsolt RD, Anton G, Blavet N, Jalfre M, (1978). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379-391.
46. Reynolds GP, Kirk SL, (2010). Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125: 169-179.
47. 6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33: 2657-2666.
48. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. (2012). Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-Analysis of head-to-head comparisons. Schizophr Bull 38: 167-177.
49. 2A receptors. Int J Neuropsychopharmacol 16: 1139-1151.
50. Scheuer K, Maras A, Gattaz WF, Cairns N, Förstl H, Müller WE, (1996). Cortical NMDA receptor properties and membrane fluidity are altered in Alzheimer's disease. Dement Basel Switz 7: 210-214.
51. Schulze J, Bussche H, Glaeske G, Kaduszkiewicz H, Wiese B, Hoffmann F, (2013). Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. Eur Neuropsychopharmacol 23: 1034-1042.
52. Siegel RK, (1978). Phencyclidine and ketamine intoxication: a study of four populations of recreational users. NIDA Res Monogr 21: 119-147.
53. Sukonick DL, Pollock BG, Sweet RA, Mulsant BH, Rosen J, Klunk WE, et al. (2001). The 5-HTTPRS/L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol 58: 1425-1428.
54. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA, (2006). Compensatory changes in the noradrenergic nervous system in the locus coeruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 26: 467-478.
55. Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, et al. (2011). Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. Am J Psychiatry 168: 831-839.
56. 2 receptor antagonist raclopride in rats. J Neural Transm 107: 1229-1238.
57. Wadenberg M-LG, (2010). Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des 16: 358-370.
58. Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. (2009). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 17: 744-751.
59. 6 receptor antagonist SB-399885 in rats. Pharmacol Rep 59: 664-671.
60. Wu J, Zou H, Strong JA, Yu J, Zhou X, Xie Q, et al. (2005). Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology (Berl) 177: 256-263.